<DOC>
	<DOCNO>NCT01066468</DOCNO>
	<brief_summary>This study ass pharmacokinetics imatinib pediatric patient age 1 &lt; 4 year age help develop dose regimen</brief_summary>
	<brief_title>Glivec/Gleevec Pediatric ( Age 1 Less Than 4 ) PK Study CML , Ph+ ALL Patients Other Glivec/Gleevec® Indicated Hematological Disorders .</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Patients must 1 less 4 year age study entry 2 . Written informed consent must sign patient 's parent legal guardian . 3 . Patients must diagnosis CML Ph+ ALL 4 . Lansky score must ≥ 50 ( Table72 ) 5 . Patient must adequate end organ function define Total bilirubin &lt; 1.5 x ULN SGPT ( ALT ) SGOT ( AST ) &lt; 2.5 x UNL Creatinine &lt; 1.5 x ULN 1 . Patients receive drug ) know metabolize CYP3A4 3A5 , b ) CYP inhibitor inducer , within 2 week prior Visit 2 ( except imatinib ) 2 . Patients previously receive radiotherapy ≥ 25 % bone marrow , exception patient receive total body radiation part preparatory regimen hematopoetic stem cell transplant ( HSCT ) 3 . Patients receive antibacterial antipyretic medication treat active infection 4 . Patients International normalized ratio ( INR ) partial thromboplastin time ( PTT ) &gt; 1.5 x ULN , exception patient treatment oral anticoagulant 5 . Patients whose parent legal guardian , opinion Investigator , unlikely comply protocol safety monitoring requirement Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>3 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Philadelphia chromosome positive</keyword>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>PhGlivec ,</keyword>
	<keyword>Gleevec ,</keyword>
	<keyword>hypereosinophilic syndrome ,</keyword>
	<keyword>HES ,</keyword>
	<keyword>chronic eosinophilic leukemia ,</keyword>
	<keyword>CEL ,</keyword>
	<keyword>myelodysplastic syndrome ,</keyword>
	<keyword>MDS ,</keyword>
	<keyword>myeloproliferative disease ,</keyword>
	<keyword>MPD+ ALL</keyword>
</DOC>